This study is performed to analyze various aspects of biofilms on ureteral stents in a longterm setting.
The study is performed to provide a better understanding of the influence of biofilms on ureteral stents on the entire spectrum of stent-associated morbidity in a longterm setting. In addition, the trial is intended to give an overview of the incidence of complaints, the occurrence of complications and their economic aspects. The influence of biofilms on the morbidity associated with longterm ureteral stenting is assessed.
Study Type
OBSERVATIONAL
Enrollment
91
Urological Department, Cantonal Hospital of St. Gallen
Sankt Gallen, Switzerland
Total biofilm mass on ureteral stents
Time frame: Time of stent removal/change: three months (range 2-4 months) after last stent insertion/change
Assessment of morbidity using the Ureteral Stent Symptom Questionnaire (USSQ)
Time frame: Day of stent removal/change: three months (range 2-4 months) after last stent insertion/change
Urine Culture
Time frame: 2-6 months after stent insertion
Number of bacteria on stent surface, if applicable number of bacteria on two indwelling stents
Time frame: 2-6 months after stent insertion
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time frame: 2-6 months after stent insertion
Assessment of costs arising from complications
complications assessed by CTCAE v4.0
Time frame: 2-6 months after stent insertion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.